{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:24:19Z","timestamp":1791138259963,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.humpath.2005.03.015","type":"journal-article","created":{"date-parts":[[2005,6,3]],"date-time":"2005-06-03T11:36:51Z","timestamp":1117798611000},"page":"486-493","source":"Crossref","is-referenced-by-count":194,"title":["Human malignant melanoma: detection of BRAF- and c-kit\u2013activating mutations by high-resolution amplicon melting analysis"],"prefix":"10.1016","volume":"36","author":[{"given":"Carlynn","family":"Willmore-Payne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Holden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Tripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester J.","family":"Layfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2005.03.015_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/science.3291115","article-title":"The protein kinase family: conserved features and deduced phylogeny of the catalytic domains","volume":"241","author":"Hunter","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.humpath.2005.03.015_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","article-title":"Protein tyrosine kinase structure and function","volume":"69","author":"Hubbard","year":"2000","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.humpath.2005.03.015_bib3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc1434","article-title":"Switching on kinases: oncogenic activation of BRAF and the PDGFR family","volume":"4","author":"Dibb","year":"2004","journal-title":"Nat Rev"},{"key":"10.1016\/j.humpath.2005.03.015_bib4","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","article-title":"Biology of gastrointestinal stromal tumors","volume":"22","author":"Corless","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2005.03.015_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J Carcinog"},{"key":"10.1016\/j.humpath.2005.03.015_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.1101637","article-title":"Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways","volume":"305","author":"Sordella","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.humpath.2005.03.015_bib7","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.humpath.2005.03.015_bib8","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/1389557043487349","article-title":"Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases","volume":"4","author":"Garcia-Echeverria","year":"2004","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.humpath.2005.03.015_bib9","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2005.03.015_bib10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"New Engl J Med"},{"key":"10.1016\/j.humpath.2005.03.015_bib11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.humpath.2005.03.015_bib12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.humpath.2005.03.015_bib13","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2005.03.015_bib14","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1200\/JCO.2003.07.116","article-title":"Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment of resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis","volume":"21","author":"Hauschild","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2005.03.015_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2004.11.950","article-title":"When will melanoma vaccines be proven effective?","volume":"22","author":"Sosman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2005.03.015_bib16","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2003.02.061","article-title":"Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma","volume":"21","author":"Hwu","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2005.03.015_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2005.03.015_bib18","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanomas","volume":"95","author":"Maldonado","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2005.03.015_bib19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1042\/0264-6021:3510289","article-title":"Meaningful relationships: the regulation of the Ras\/Raf\/MEK\/ERK pathway by protein interactions","volume":"351","author":"Kolch","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.humpath.2005.03.015_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1535-6108(03)00189-2","article-title":"BRAF as a potential therapeutic target in melanoma and other malignancies","volume":"4","author":"Tuveson","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2005.03.015_bib21","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1038\/sj.onc.1207785","article-title":"B-RAF is a therapeutic target in melanoma","volume":"23","author":"Karasarides","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2005.03.015_bib22","first-page":"5198","article-title":"Suppression of BRAFV599E in human melanoma abrogates transformation","volume":"63","author":"Hingorani","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2005.03.015_bib23","doi-asserted-by":"crossref","first-page":"6031","DOI":"10.1038\/sj.onc.1207812","article-title":"Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference","volume":"23","author":"Sumimoto","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2005.03.015_bib24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/erc.0.0080219","article-title":"Discovery of a novel Raf kinase inhibitor","volume":"8","author":"Lyons","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.humpath.2005.03.015_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1309\/R8N1CN04KKFV6M7T","article-title":"Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotype","volume":"122","author":"Kovach-Guerriere","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2005.03.015_bib26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-3163-2-8","article-title":"Immunohistochemical determination of HER-2\/neu overexpression in malignant melanoma reveals no prognostic value, while c-kit (CD 117) overexpression exhibits potential therapeutic implications","volume":"2","author":"Potti","year":"2003","journal-title":"J Carcinog"},{"key":"10.1016\/j.humpath.2005.03.015_bib27","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1309\/4E6UYBY62N2FCA6N","article-title":"Detection of c-kit\u2013activating mutations in gastrointestinal stromal tumors by high resolution amplicon melting analysis","volume":"122","author":"Willmore","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2005.03.015_bib28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/jmg.2003.016667","article-title":"Absence of BRAF mutations in UV-protected mucosal melanomas","volume":"41","author":"Edwards","year":"2004","journal-title":"J Med Genet"},{"key":"10.1016\/j.humpath.2005.03.015_bib29","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2005.03.015_bib30","first-page":"939","article-title":"Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression","volume":"10","author":"Montone","year":"1997","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2005.03.015_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.2910520207","article-title":"Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor","volume":"52","author":"Natali","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2005.03.015_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/modpathol.3880504","article-title":"c-Kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant","volume":"15","author":"Wardelmann","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2005.03.015_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/00125480-200201000-00007","article-title":"CD117 (KIT): a diverse protein with selective applications in surgical pathology","volume":"9","author":"Gibson","year":"2002","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.humpath.2005.03.015_bib34","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0002-9440(10)63120-3","article-title":"Kit mutations are common in testicular seminomas","volume":"164","author":"Kemmer","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2005.03.015_bib35","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.humpath.2005.03.015_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/jcb.20296","article-title":"Regulation of gene expression in melanoma: new approaches for treatment","volume":"94","author":"Leslie","year":"2005","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.humpath.2005.03.015_bib37","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1200\/JCO.2004.10.125","article-title":"Prevalence of KIT expression in human tumors","volume":"22","author":"Went","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817705001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817705001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T03:59:54Z","timestamp":1548475194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817705001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0046817705001668"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2005.03.015","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}